What exactly is durvalumab/Infinifer?

Durvalumab/Infinifer (Durvalumab) is an innovative immunotherapy drug that belongs to the programmed death ligand 1 (PD-L1) inhibitor class of monoclonal antibodies. By targeting PD-L1, it blocks the immunosuppressive signals between tumor cells and T cells, allowing the patient's own immune system to recognize and attack tumor cells, thereby playing an anti-cancer role in a variety of solid tumors. This mechanism is different from traditional chemotherapy drugs. Chemotherapy usually relies on directly killing tumor cells, while immune checkpoint inhibitors achieve tumor control by restoring immune activity. This is also an important symbol of the development of cancer treatment from cytotoxicity to precision immunity in recent years.

Internationally, durvalumab has been approved for a variety of indications, including unresectable locally advanced small cell lung cancer, non-small cell lung cancer (NSCLC), and urothelial cancer. In NSCLC, durvalumab is usually used as maintenance therapy after chemotherapy and radiotherapy, aiming to delay disease progression and improve patients' progression-free survival (PFS) and overall survival (OS). It has the advantage of being able to provide further disease control after conventional therapy without adding significant systemic toxicity, which is particularly important for patients with lung cancer.

The drug properties of durvalumab also include intravenous infusion administration every two weeks or every four weeks to facilitate clinical management. Because it is a fully humanized monoclonal antibody, it is relatively well tolerated. Most of the immune-related adverse reactions are rash, enteritis or thyroid dysfunction, which can be managed through standardized monitoring and early intervention. This controllability enables long-term maintenance of durvalumab in clinical practice, bringing sustained therapeutic benefits to patients.

It is worth noting that as aPD-L1 inhibitor, the efficacy of durvalumab is usually related to the PD-L1 expression level of tumor tissue. Patients with high expression show more pronounced benefit in clinical trials, while patients with low expression may have relatively limited responses.

Reference materials:https://www.imfinzi.com/